Profiling Sirolimus-Induced Inflammatory Syndrome: A Prospective Tricentric Observational Study

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Buron, Fanny ^a,b   Malvezzi, Paolo ^c   Villar, Emmanuel ^d   Chauvet, Cécile ^a   Janbon, Bénédicte ^c   Denis, Laure ^d   Brunet, Maria ^a   Daoud, Sameh ^a   Cahen, Rémi ^d   Pouteil Noble, Claire ^a,b,d   Gagnieu, Marie Claude ^a,b   Bienvenu, Jacques ^b,d,e   Bayle, François ^c   Morelon, Emmanuel ^a,b,e   Thaunat, Olivier ^a,b,e  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CYCLOSPORIN A; HEMOGLOBIN; INTERLEUKIN 6; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ACNE; ADULT; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY TRANSPLANTATION; MALE; NEGATIVE FEEDBACK; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SIROLIMUS INDUCED INFLAMMATORY SYNDROME; STOMATITIS;

ADULT; AGED; CALCINEURIN; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872050913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053078     Document Type: Article

References (35)

1. Groth CG, Backman L, Morales JM, Calne R, Kreis H, et al. (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67: 1036-1042.
2. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB, (2002) Strategies to improve long-term outcomes after renal transplantation. The New England journal of medicine 346: 580-590.
3. Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, et al. (2005) Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 16: 3755-3762.
4. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, et al. (2007) Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 7: 1722-1732.
5. Segundo DS, Ruiz JC, Izquierdo M, Fernandez-Fresnedo G, Gomez-Alamillo C, et al. (2006) Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 82: 550-557.
6. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW, (2005) Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 5: 228-236.
7. Thomson AW, Turnquist HR, Raimondi G, (2009) Immunoregulatory functions of mTOR inhibition. Nature reviews 9: 324-337.
8. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, et al. (2007) Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 178: 7018-7031.
9. Andrassy J, Graeb C, Rentsch M, Jauch KW, Guba M, (2005) mTOR inhibition and its effect on cancer in transplantation. Transplantation 80: S171-174.
10. Cravedi P, Ruggenenti P, Remuzzi G, (2010) Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney international 78: 1068-1074.
11. Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, et al. (2007) Sirolimus in renal transplantation. Nephrol Dial Transplant 22Suppl 8: viii61-viii65.
12. Zuber J, Anglicheau D, Elie C, Bererhi L, Timsit MO, et al. (2008) Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 8: 1471-1479.
13. Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Peraldi MN, et al. (2007) High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 326-333.
14. Letavernier E, Bruneval P, Vandermeersch S, Perez J, Mandet C, et al. (2009) Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 24: 630-638.
15. Mahe E, Morelon E, Lechaton S, Sang KH, Mansouri R, et al. (2005) Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 79: 476-482.
16. Rana JS, Sheikh J, (2007) Serum sickness-like reactions after placement of sirolimus-eluting stents. Ann Allergy Asthma Immunol 98: 201-202.
17. Molinari M, Al-Saif F, Ryan EA, Lakey JR, Senior PA, et al. (2005) Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. Am J Transplant 5: 2799-2804.
18. Champion L, Stern M, Israel-Biet D, Mamzer-Bruneel MF, Peraldi MN, et al. (2006) Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Annals of internal medicine 144: 505-509.
19. Thaunat O, Beaumont C, Chatenoud L, Lechaton S, Mamzer-Bruneel MF, et al. (2005) Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 80: 1212-1219.
20. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, et al. (2002) Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74: 1070-1076.
21. McCormack HM, Horne DJ, Sheather S, (1988) Clinical applications of visual analogue scales: a critical review. Psychological medicine 18: 1007-1019.
22. Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, et al. (2005) Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 5: 595-603.
23. Augustine JJ, Rodriguez V, Padiyar A, Bodziak KA, Schulak JA, et al. (2008) Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium. Transplantation 86: 548-553.
24. Fishbane S, Cohen DJ, Coyne DW, Djamali A, Singh AK, et al. (2009) Posttransplant anemia: the role of sirolimus. Kidney international 76: 376-382.
25. Maiorano A, Stallone G, Schena A, Infante B, Pontrelli P, et al. (2006) Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 82: 908-912.
26. Thaunat O, Beaumont C, Lechaton S, Kreis H, Morelon E (2007) Late introduction of sirolimus induces anemia in renal transplant recipients. Transplantation 83: 1283; author reply 1284.
27. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, et al. (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. The Journal of clinical investigation 110: 1037-1044.
28. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F, (2005) Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood 106: 3979-3984.
29. Malyszko J, (2009) Hepcidin assays: ironing out some details. Clin J Am Soc Nephrol 4: 1015-1016.
30. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE, (1991) Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. The Journal of experimental medicine 174: 1209-1220.
31. Nathan C, (2002) Points of control in inflammation. Nature 420: 846-852.
32. Baker AK, Wang R, Mackman N, Luyendyk JP, (2009) Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression. Molecular immunology 46: 2249-2255.
33. Jorgensen PF, Wang JE, Almlof M, Solberg R, Okkenhaug C, et al. (2001) Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. Scandinavian journal of immunology 53: 184-191.
34. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, et al. (2008) The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29: 565-577.
35. Brouard S, Puig-Pey I, Lozano JJ, Pallier A, Braud C, et al. (2010) Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy. Am J Transplant 10: 2604-2614.